Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX)’s stock price has plunge by 0.10relation to previous closing price of 393.10. Nevertheless, the company has seen a -1.69% plunge in its stock price over the last five trading sessions. The Motley Fool reported 2024-04-18 that Vertex Pharmaceuticals will acquire Alpine Immune Sciences for $4.9 billion. Alpine Immune Sciences’ leading candidate looks highly promising.
Is It Worth Investing in Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) Right Now?
The price-to-earnings ratio for Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) is above average at 28.33x, Company’s 36-month beta value is 0.39.Analysts have differing opinions on the stock, with 12 analysts rating it as a “buy,” 10 as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for VRTX is 257.54M, and currently, short sellers hold a 1.54% ratio of that floaft. The average trading volume of VRTX on April 19, 2024 was 1.24M shares.
VRTX’s Market Performance
VRTX’s stock has seen a -1.69% decrease for the week, with a -5.23% drop in the past month and a -9.12% fall in the past quarter. The volatility ratio for the week is 1.48%, and the volatility levels for the past 30 days are at 1.62% for Vertex Pharmaceuticals, Inc. The simple moving average for the last 20 days is -3.44% for VRTX stock, with a simple moving average of 3.10% for the last 200 days.
Analysts’ Opinion of VRTX
Many brokerage firms have already submitted their reports for VRTX stocks, with Evercore ISI repeating the rating for VRTX by listing it as a “Outperform.” The predicted price for VRTX in the upcoming period, according to Evercore ISI is $438 based on the research report published on April 11, 2024 of the current year 2024.
Wolfe Research, on the other hand, stated in their research note that they expect to see VRTX reach a price target of $515. The rating they have provided for VRTX stocks is “Outperform” according to the report published on February 15th, 2024.
Evercore ISI gave a rating of “In-line” to VRTX, setting the target price at $438 in the report published on February 06th of the current year.
VRTX Trading at -5.11% from the 50-Day Moving Average
After a stumble in the market that brought VRTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -12.25% of loss for the given period.
Volatility was left at 1.62%, however, over the last 30 days, the volatility rate increased by 1.48%, as shares sank -4.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.44% lower at present.
During the last 5 trading sessions, VRTX fell by -1.69%, which changed the moving average for the period of 200-days by +13.21% in comparison to the 20-day moving average, which settled at $406.59. In addition, Vertex Pharmaceuticals, Inc. saw -3.30% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VRTX starting from Ambrose Kristen, who sale 240 shares at the price of $419.00 back on Apr 02 ’24. After this action, Ambrose Kristen now owns 7,500 shares of Vertex Pharmaceuticals, Inc., valued at $100,560 using the latest closing price.
Arbuckle Stuart A, the EVP, COO of Vertex Pharmaceuticals, Inc., sale 5,034 shares at $425.70 during a trade that took place back on Feb 26 ’24, which means that Arbuckle Stuart A is holding 49,691 shares at $2,142,974 based on the most recent closing price.
Stock Fundamentals for VRTX
Current profitability levels for the company are sitting at:
- 0.39 for the present operating margin
- 0.87 for the gross margin
The net margin for Vertex Pharmaceuticals, Inc. stands at 0.37. The total capital return value is set at 0.2. Equity return is now at value 22.99, with 17.56 for asset returns.
Based on Vertex Pharmaceuticals, Inc. (VRTX), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at 4.38. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is 86.22.
Currently, EBITDA for the company is 3.93 billion with net debt to EBITDA at -2.0. When we switch over and look at the enterprise to sales, we see a ratio of 9.33. The receivables turnover for the company is 6.31for trailing twelve months and the total asset turnover is 0.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.99.
Conclusion
In a nutshell, Vertex Pharmaceuticals, Inc. (VRTX) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
